Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data
Sean McCann(University of North Carolina at Chapel Hill), Daniel González(University of North Carolina at Chapel Hill), Victória Etges Helfer(University of North Carolina at Chapel Hill), Marisa Meyer(Nemours Children's Health System), Sarah G. Anderson(Emmes (United States)), Stephen J. Balevic(Duke University), William J. Muller(Lurie Children's Hospital), Amira Al‐Uzri(Oregon Health & Science University), Sitora Turdalieva(Emmes (United States)), John van den Anker(Children's National), Andrea N. Edginton(University of Waterloo)
Cited by 3
Related Papers
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
|Clinical Infectious Diseases|2022|201